Mein Abitur liegt nun bereits acht Jahre zurück – ich erschrecke jedes Mal, wenn ich nur darüber nachdenke. In den Jahren nach meinem Abschluss hat meine ehemalige Oberstufe ein Programm aufgebaut, bei dem frühere Schüler über ihren Werdegang und ihre aktuelle Position berichten. Ich unterstütze solche Aktionen sehr gerne und habe immer ein großes Interesse bei den Schülern wahrgenommen. Daher stand für mich sofort fest: In diesem Jahr bin ich wieder mit dabei. Jedoch wollte ich meine sehr einseitig gewordene Präsentation über Studieninhalte und Jobbeschreibungen etwas modernisieren – oder sollte ich sagen »digitalisieren«?
Und das hat sich gelohnt! Die Schüler sind dem Thema »Digitalisierung« offen, neugierig und mit Spaß begegnet und ich habe wertvolle Erkenntnisse über die nächste Generation gewonnen.
Introduction Big Data in the Life Science and Pharmaceutical Industry
A key driving factor in the life science and pharmaceutical industry is the possibility to handle large volumes of data in order to access, manage and analyze the data. To be able to gain business efficiency and a good performance, the drug development needs to take place in a best time to market relationship. Therefore, more completed clinical trials are necessary in a shortened timeframe. An acceleration in the drug development leads to an improved drug pipeline, less costs and faster product releases and therefore better profitability.
When introducing new systems or adding new areas to a new system usually data migrations are needed to integrate the data from the old system or other areas into the new system. During such data migrations often a migration tool is used to get the data from the source into the target system. This migration tool transforms the data to be compliant with the new system and imports the data into the system.
In such a scenario generally these questions come up: How to validate the data migration? Do we need to validate the tool itself? Do we need to validate all details of all rules and functionalities that are available in the tool and could be used in theory?
The implementation of a standardized DMS like D2 or the > Dell EMC Documentum Life Sciences Solution Suite requires the migration of documents from the old to the new system or a transforming of the data model within the system in order to work properly with the new application. Often this old data is not fully standardized and structured, but either based on a less controlled system such as Documentum Webtop or on a controlled system with slightly different structures such as CSC FirstDoc or Cara.
I’ve been in the Document Management System (DMS) / Enterprise Content Management System (ECMS) market for more than 20 years. Sometimes very focused on a specific aspect e.g. Technical Documentation, sometimes more general e.g. ECMS platform and sometimes with focus on an industry segment e.g. Life Science. I have seen a lot of vendors, products and technologies coming and going. The latest acquisition and certainly the biggest one was just a week ago. Hopefully, this will not reduce the power of innovation.
Interesting announcement from Alfresco. They started an aggressive > swap out program against Documentum pushing the fear that Documentum is going away or going south soon. First of all, Alfresco is a really good ECM platform – fme has been an Alfresco partner for many years. There might be good reasons for the one or the other company to decide to change their ECM platform within the next weeks or months, but it should have nothing to do with the OpenText acquisition. Fear has always been a bad advisor. Documentum is not going away any time soon, or why do you think OpenText payed 1,6 billion USD? They have to keep up the flow of maintenance money for quite some years to make the deal work.
Mobile apps and Big Data are important topics, which are more and more relevant in the Life Science Industry. New media is available on a global base. That’s the reason why people and companies have to adapt their processes to this new digital age. People search for information on the internet and often trust blogs or forums more than the old fashioned ways. For medical problems they do not only trust doctors, but inform themselves on the web. The new social media has big influence on the ways on how information is provided and received. Also the way of interactive information exchange has changed. Formulas are used in a digital way, either on websites or also on mobile apps. Therefore data has to be accessed in a global way. Mobile apps are used outside of secure networks; therefore, also the related data has to be stored secure in a global way, which allows access from the internet.
Although both industries – Discrete Manufacturing and Process Manufacturing – are completely different, I see some similarities.
10 years ago, the only competitive threat for a traditional OEM came from another traditional OEM. All R&D Managers had an arrogant smile on the face when they heard about a small US company, which was entering the market with electric cars. Today this company – Tesla – is also an established player. But new competitors do appear on the horizon: Apple, Google, Uber and others. Companies with no knowledge about how to build, sell and maintain a car. Why is this possible?
Document management is no longer greenfield terrain. By now many companies have already determined their need for a document management system and understand the benefits it offers them, especially in the Life Sciences. For this reason, nearly every company dealing with mission-critical documents has implemented some sort of solution in recent years.
The question that is now more likely to arise is whether the performance level and user friendliness of today’s system are still adequate, and/or capable of meeting growing requirements. And it could be that other providers have developed a newer, more attractive solution.
Word has gotten around that big data is a new and promising IT discipline. There are many examples of successful big data applications. They include connected cars, mobile adversing and security analytics just to name a few. Not much is heard from the life science industry. Clearly the lines between medical devices and lifestyle products such as fitness trackers are gradually blurring.
Bitkom surveyed 102 companies from the pharmaceuticals sector about the digital transformation in 2015. According to this survey, 97 per cent of pharmaceutical companies believe that lifestyle products are going to make a significant contribution to operating results in the future. These companies would therefore hold an important component of the new value chain: the sensor that records a variety of vital functions.